KSI-501 is under clinical development by Kodiak Sciences and currently in Phase I for Diabetic Macular Edema. According to GlobalData, Phase I drugs for Diabetic Macular Edema have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KSI-501’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KSI-501 overview

KSI-501 is under development for the treatment of diabetic macular edema, wet age-related macular degeneration and uveitis. The drug candidate is a bispecific antibody conjugated with phosphorylcholine biopolymer. It is formulated as a solution and administered through the intravitreal route. It acts by targeting VEGF, PIGF and IL-6. It is developed based on the antibody biopolymer conjugate (ABC) platform.

It was under development for the treatment of diabetic retinopathy and Coronavirus COVID-19 disease.

Kodiak Sciences overview

Kodiak Sciences is a biopharmaceutical company that develops and transformative therapeutics to treat retinal diseases. Its pipeline products includes tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer, which treats wet age-related macular degeneration (AMD); KSI-501, a bispecific conjugate for pro-inflammatory cytokine interleukin-6 (IL-6) and anti-vascular endothelial growth factor (VEGF) and KSI-101, unconjugated bispecific protein that targets interleukin-6 (IL-6) and anti-vascular endothelial growth factor (VEGF) developed for retinal inflammatory conditions. Kodiak Sciences is headquartered in Palo Alto, California, the US.

For a complete picture of KSI-501’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.